Want to see AU:IXC full AI Analyst Report?
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.18
Previous CloseN/A
Volume14.00K
Average Volume (3M)49.57K
Market Cap
AU$9.77M
Enterprise ValueAU$4.42
Total Cash (Recent Filing)AU$4.60M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Feb 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (zero Debt)A zero‑debt balance sheet materially reduces fixed financial obligations and bankruptcy risk, giving management structural optionality to prioritize R&D and clinical milestones. This durable conservatism supports longer runway for trials and strategic choices without servicing debt.
Focused Clinical-stage Pipeline (Presendin For IIH)A single, well-defined development program (Presendin for IIH) concentrates expertise and capital on one regulatory pathway, improving execution odds versus a scattered pipeline. For a small biotech, focus can accelerate trial design, regulatory engagement, and topline readouts that drive long‑term value.
Improving Cash Outflows In Latest YearReduced cash outflows indicate management has begun to steady burn through cost control or more efficient operations. If sustained, this improvement extends the company's funding runway, increasing the chance it can reach clinical or regulatory inflection points before needing new capital.
Bears Say
Persistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow is a structural constraint: the company cannot self‑finance operations and will depend on external funding. Over months, this forces dilution, limits discretionary R&D spend, and raises execution risk for late‑stage trials.
Highly Volatile And Steeply Declining RevenueA small, volatile revenue base with an ~81% decline indicates weak or inconsistent commercial traction. Structurally, this undermines the firm's ability to demonstrate sustainable demand, complicates margin recovery, and reduces non‑dilutive funding options like reinvesting revenue.
Declining Equity And Dilution RiskMaterial erosion of equity over multiple years signals repeated financing or accumulated losses, creating durable dilution risk for shareholders. Reliance on external capital can shift governance, compress future returns, and constrain strategic choices if funding terms become unfavorable.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.09 and its highest was AU$0.18 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$9.77M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Feb 18, 2027 which is in 172 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Currently, no data Available
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Technical Analysis
Acrux
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Argenica Therapeutics Ltd
―
Botanix Pharmaceuticals Limited
―